By JULIE EGGINGTON, EKATERINA CLEARY & LEEZA OSIPENKO
When CMS issued its Request for Data below the Complete Rules to Uncover Suspicious Healthcare (CRUSH) initiative in February, it zeroed in on a long-festering drawback: fraud, waste, and abuse in laboratory testing, particularly in genetic and molecular diagnostics.
The laboratory trade will reply. And when it does, its arguments will sound polished, acquainted, and deeply reassuring. They may even be both disingenuous or unproven.
If policymakers need this effort to succeed, they need to be ready to deal with three claims which have lengthy shielded problematic practices from significant oversight.
Declare 1: Fraud, waste and abuse is restricted to some unhealthy actors
Count on labs to argue that fraud, waste, and abuse is uncommon, remoted, and already addressed by enforcement actions. The narrative will characteristic a handful of egregious cases, offered as outliers in an in any other case reliable ecosystem.
However the issue will not be a couple of rotten apples. It’s the orchard’s design.
Take “code stacking” for instance, during which laboratories invoice a number of particular person genetic take a look at codes reasonably than a single panel code, typically inflating reimbursement. In one analysis, laboratories used between 1 and 12 billing codes for hereditary most cancers panels with the identical indications for testing, with estimated common expenses starting from $679 to $8,589 for ostensibly comparable assessments. The repetition of those behaviors throughout corporations suggests systemic incentives, not remoted misconduct.
Ample Medicare billing knowledge, whistleblower cases, and Department of Justice settlements level to patterns, not anomalies: high-volume genetic panels ordered with little medical justification, molecular pathology assessments billed below grab bag and overly permissive billing codes, and aggressive marketing and patient harvesting practices concentrating on susceptible populations.
A key driver is opacity. Many laboratory-developed assessments (LDTs) are marketed under similar or identical names regardless of significant variations in design, accuracy, and supposed use. To a clinician or payer, they seem interchangeable. In actuality, they aren’t.
This naming ambiguity permits lower-quality assessments to experience the coattails of better-validated ones, whereas nonetheless commanding reimbursement. Fraud, on this context, will not be all the time a dramatic act. It’s typically embedded in routine billing.
Declare 2: Precision medication superior by genetics is value the associated fee on account of improved affected person outcomes
The second argument will attraction to aspiration. Labs will emphasize that genetic testing is the spine of precision medication and subsequently a worthwhile funding for CMS, regardless of the ballooning prices.
Laboratory lobbyists and trade teams will use the ‘age of precision medication’ argument to justify the truth that genetic testing is now costing Medicare virtually as a lot as all different outpatient laboratory testing mixed. In the newest evaluation from 2024 Medicare data, genetic assessments accounted for 43% ($3.6 billion) of whole Medicare outpatient laboratory spending, regardless of representing solely 5% of all Medicare outpatient laboratory assessments carried out.
There may be some reality right here to the worth of genetic assessments. Selected genetic tests have demonstrated clear medical utility, bettering prognosis, or guiding therapy that has resulted within the extension of life.
However the leap from “some” assessments resulting in improved affected person outcomes to “most” assessments resulting in improved affected person outcomes is the place the argument breaks down.
The proof base for a lot of marketed genetic and molecular assessments remains thin, heterogeneous, or entirely absent. Medical utility, within the uncommon situations the place customers or a take a look at developer has demonstrated it, is commonly prolonged as a halo over different assessments from totally different labs providing equally marketed assessments. Whereas the me-too unproven assessments share practical branding and billing codes with the confirmed take a look at, they typically differ in methodology or efficiency in nontransparent methods. In brief, on account of inherent variations in methodologies, the me-too assessments could not enhance affected person outcomes on the similar effectiveness because the confirmed take a look at, and maybe under no circumstances.
This isn’t precision medication. It’s approximation at scale.
For policymakers, the excellence issues. With out proof {that a} take a look at informs medical selections in a method that improves well being, its worth to Medicare and Medicaid stays unproven.
If labs want to declare that their assessments save or enhance lives, they have to show it for every distinct take a look at, whether or not or not it’s market chief assessments or the me-too assessments.
Declare 3: Oversight on labs slows innovation on the expense of lives saved
Lastly, anticipate labs to challenge a warning: stricter oversight of labs’ affected person recruitment and billing practices will gradual innovation, delay entry to cutting-edge diagnostics, and finally hurt sufferers.
This argument rests on a crucial assumption that has not been established, particularly that the present quantity and acceleration of precision medication associated laboratory testing is delivering life-saving profit at scale.
In lots of circumstances, that proof doesn’t exist, or exists to the contrary.
Innovation in healthcare will not be outlined by the variety of assessments medical doctors order for sufferers, or the growing complexity and expense of molecular pathology testing, however by their impression on affected person outcomes. Requiring that the suitable sufferers obtain the suitable assessments (which have confirmed utility), on the proper time, doesn’t inherently suppress innovation; it helps distinguish between significant advances and the noise
Well documented efforts by some genetics labs to recruit as many sufferers as doable leads to the dilution of the true worth of genetic testing. Even when, for instance, a most cancers genetic testing laboratory has a take a look at with confirmed medical utility for sufferers with sure cancers, testing sufferers with out the related cancers would dilute its measurable medical utility. And as a result of existence of false positives in diagnostics, testing sufferers recruited inappropriately might finally hurt extra sufferers than the take a look at helps.
Moreover, the absence of billing requirements can distort innovation. When reimbursement is offered with out sturdy proof necessities, the market rewards proliferation over validation. With out oversight, high-quality assessments should compete with lower-cost, lower-evidence options which can be marketed as equal or higher than the confirmed assessments.
Stricter oversight of laboratories affected person recruitment and requests for reimbursement would supply CMS alternative to make sure that the targets of precision medication are achieved. It might not halt innovation. It might redirect it towards demonstrable worth.
A path ahead
If CMS needs to cut back fraud, waste, and abuse in laboratory testing, it ought to focus much less on chasing particular person unhealthy actors – which is proving to be an infinite sport of whack-a-mole – and extra on correcting structural weaknesses.
That begins with transparency. Assessments that differ in design or efficiency shouldn’t share indistinguishable names in billing methods. Clear differentiation would make it tougher for lower-quality assessments to masquerade as established ones.
It additionally requires proof self-discipline. Protection and reimbursement ought to be tied to demonstrated medical utility on the take a look at stage, not inferred from category-level proof.
The CRUSH RFI presents a possibility to reset expectations. The laboratory trade will make its case. CMS ought to be able to look previous the acquainted narratives and ask an easier query: not whether or not a take a look at might advance medication, however whether or not it does.
Julie Eggington is CEO of the Middle for Genomic Interpretation and founding father of Grandview Consulting. Ekaterina Cleary is a Knowledge Scientist and Leeza Osipenko is CEO at Consilium Scientific, the place she leads the event of This submit is a part of their work at Evimeter, a quantitative framework for evaluating the power of medical proof supporting breakthrough medical gadgets and diagnostics, funded by Arnold Ventures.
